Who owns GoodRx? Ownership structure explained (2026)

GoodRx runs the largest prescription price comparison platform in the United States. It aggregates cash prices and pharmacy discount codes across tens of thousands of drugstores, letting uninsured and underinsured Americans pay less at the counter than they would without a coupon. The service is free to users, and GoodRx earns fees from the pharmacy benefit managers that process the discounted transactions.

The company grew quickly by solving a problem created by the opacity of US drug pricing, a market where a lower cash price pulls in shoppers who would otherwise skip a fill, a sign of high price elasticity of demand. It attracted private equity capital, went public at a high-profile valuation in 2020, then lost most of that value as a single pharmacy dispute and slowing prescription volumes exposed the fragility of its core business. That history is written into its ownership structure.

Understanding who owns GoodRx matters because control of the company sits with a small group of founders and private equity sponsors, not with the public shareholders who buy its Class A stock. A dual-class share structure gives that inner circle voting power far out of proportion to the economic stake held by ordinary investors. Ownership determines who steers a business that handles sensitive health data for millions of Americans.

GoodRx was founded in 2011 in Santa Monica, California, by Doug Hirsch, Trevor Bezdek, and Scott Marlette. Hirsch had been one of the earliest employees at Yahoo and later a vice president of product at Facebook, now Meta. Marlette was an early Facebook engineer who built Facebook Photos. Bezdek, a Stanford graduate in biology and computer science, had already started two companies before GoodRx.

The founders built GoodRx around a simple observation: the same drug can cost wildly different amounts at different pharmacies, and cash prices are often lower than insurance copays. GoodRx collects pricing data and negotiated discount rates, then shows consumers where to fill a prescription for less. Its core revenue comes from pharmacy benefit managers, which pay GoodRx a fee each time a consumer uses one of its codes. The company has since added a subscription plan, a telehealth marketplace, and a pharmaceutical manufacturer solutions business it calls Pharma Direct.

GoodRx reported full-year 2025 revenue of $796.9 million, up modestly from 2024, with net income of $30.4 million and adjusted EBITDA of $270.5 million. Growth in 2025 came largely from a 41% jump in Pharma Direct revenue to $151.4 million, which offset declines in prescription transactions and subscriptions. For 2026 the company guided revenue lower, to a range of $750 million to $780 million.

GoodRx Holdings, Inc. trades on the Nasdaq under the ticker GDRX. It completed its initial public offering on September 23, 2020, pricing 34.6 million Class A shares at $33.00 each. The company had a market capitalization of roughly $1.0 to $1.3 billion in mid-2026, a steep fall from the roughly $12.7 billion valuation implied by its IPO price. Being public, however, does not mean control rests with the market. GoodRx uses a dual-class share structure that concentrates voting power in a small group of insiders.

GoodRx has two classes of common stock. Class A shares, the ones the public buys, carry one vote each. Class B shares carry ten votes each and are held by the founders and the private equity firms that backed the company before it went public. As of April 2024, Class B stock represented approximately 96.8% of total voting power, even though it is a minority of the economic value now that the public float has grown.

Exact personal stakes for Doug Hirsch and Trevor Bezdek are not broken out cleanly in a single figure, because much of the founders' and sponsors' ownership is held through investment vehicles. What is clear from filings is that the high-vote Class B stock sits with the founders and the three private equity sponsors, and that block controls the shareholder vote. Public Class A holders, despite owning a large share of the economics, hold only a small fraction of the votes.

Because GoodRx is public, its ownership is best understood as a table of major shareholders and share classes rather than venture funding rounds. The private equity firms that recapitalized GoodRx before the IPO remain its anchor owners:

Note: Stakes shift with share repurchases and index rebalancing. GoodRx bought back 48.9 million Class A shares for $217.4 million in 2025, which changes the percentages over time. Figures above reflect reporting from 2025 and early 2026.

Francisco Partners, a technology-focused private equity firm, first invested in GoodRx in 2015 and is the single largest shareholder, holding roughly 16.9% of the company and retaining board representation. Its long tenure makes it the most influential outside owner.

Silver Lake, one of the largest technology investment firms in the world, made a strategic investment in GoodRx in 2018 that valued the company at about $2.8 billion and gave it roughly a third of the equity at the time. Silver Lake held about 8.9% as of 2025 and holds board seats.

Spectrum Equity also invested in 2015, alongside Francisco Partners, and remained an owner and board member through and after the IPO. Together the three private equity firms have been reported to hold a majority of GoodRx's stock.

The Vanguard Group and BlackRock, the two dominant index fund managers, hold roughly 11.2% and 9.7% respectively. They own Class A shares, so their economic stake is large but their voting influence is limited by the dual-class structure.

GoodRx trades publicly but is controlled privately in effect. The combination of super-voting Class B stock and concentrated ownership among founders and private equity sponsors means public shareholders cannot outvote the insider block on matters such as board elections or a potential sale. This "controlled company" arrangement is disclosed in GoodRx filings and exempts the company from some Nasdaq board-independence requirements.

Wendy Barnes has served as president and chief executive officer of GoodRx since January 2025. She brought more than 30 years of pharmacy and pharmacy benefit experience to the role, including a stint as CEO of RxBenefits and time as president of Express Scripts Pharmacy. Her appointment marked a shift toward operational leadership from the pharmacy industry rather than the founder-led model of GoodRx's first decade.

Doug Hirsch and Trevor Bezdek ran GoodRx as co-CEOs from its founding until April 2023, when they stepped back and former GoDaddy chief executive Scott Wagner took over as interim CEO. Hirsch became chief mission officer and Bezdek became chairman of the board. Through their Class B holdings, the founders remain central to who controls GoodRx even though neither runs it day to day. Scott Marlette, the third co-founder, left operating roles years ago and is now a venture investor.

GoodRx's board reflects its ownership. It includes the founders and directors representing the private equity sponsors, alongside independent directors. Silver Lake and Francisco Partners have held board seats tied to their large stakes. Because the founder and sponsor block controls the vote, board composition is effectively decided by that group rather than by the broader shareholder base.

In February 2023, the Federal Trade Commission secured a $1.5 million civil penalty from GoodRx in the first enforcement action under its Health Breach Notification Rule. The FTC alleged that GoodRx had shared users' prescription and health-condition data with advertising platforms including Facebook, now Meta, and Google through tracking pixels and software development kits, despite promising not to. GoodRx denied wrongdoing but agreed to a settlement barring it from sharing health data for advertising. The case cut to the heart of GoodRx's business, which depends on consumer trust with sensitive medical information.

GoodRx depends on a small number of pharmacy benefit managers and retail pharmacy chains for its transaction revenue. In 2022 a dispute with a major grocery pharmacy chain removed some of GoodRx's discount pricing from that retailer, cutting monthly active consumers and helping trigger a collapse in the share price. The episode showed how dependent GoodRx is on partners it does not control, a structural risk that ownership cannot insulate.

GoodRx has lost most of its public-market value since 2020. Management has responded with large share repurchases, buying back nearly 49 million Class A shares in 2025 alone. Buybacks return cash to selling shareholders and can support the stock, but they also concentrate remaining ownership further in the hands of the insiders holding Class B stock.

GoodRx is a public company that is controlled like a private one. The dual-class structure means the founders and the three private equity sponsors, Francisco Partners, Silver Lake, and Spectrum Equity, together decide the company's direction, while public Class A shareholders supply capital without meaningful voting power. That gap between economic ownership and control is the defining feature of GoodRx's ownership.

For public investors, this structure limits their ability to force change even after a steep decline in the share price. They can sell, but they cannot easily replace the board or push through a sale against the wishes of the controlling block. The private equity sponsors, by contrast, retain the leverage to pursue a strategic exit or take the company private if they judge the public markets are undervaluing it.

For GoodRx as a business, concentrated ownership provides stability and patient capital, which matters in a company still reshaping its product mix toward pharmaceutical manufacturer partnerships and away from its shrinking coupon-transaction base. The same concentration, however, ties the company's fate to the return expectations of private equity owners who have held their stakes for a decade or more.

For users, ownership shapes how carefully GoodRx handles the health data at the center of its service. The 2023 FTC penalty showed what happens when a company monetizes sensitive information without adequate safeguards. Whoever controls GoodRx sets the priorities that determine whether that mistake is repeated.

Wendy Barnes is the president and CEO of GoodRx, a role she has held since January 2025. She previously led RxBenefits and served as president of Express Scripts Pharmacy. She succeeded interim CEO Scott Wagner, who ran the company after co-founders Doug Hirsch and Trevor Bezdek stepped down as co-CEOs in 2023.

Yes. GoodRx Holdings, Inc. trades on the Nasdaq under the ticker GDRX. It went public in September 2020 at $33.00 per share. Its market capitalization in mid-2026 was roughly $1.0 to $1.3 billion, well below its IPO-era value.

GoodRx was founded in 2011 by Doug Hirsch, Trevor Bezdek, and Scott Marlette. Hirsch was an early Yahoo employee and a former Facebook product vice president. Marlette was an early Facebook engineer. Bezdek was a repeat founder with a Stanford background in biology and computer science.

The largest shareholders are the private equity firms Francisco Partners (about 16.9%), Silver Lake (about 8.9%), and Spectrum Equity, which together hold a controlling block of high-vote Class B stock alongside the founders. Index managers Vanguard (about 11.2%) and BlackRock (about 9.7%) hold large stakes in the public Class A shares.

GoodRx was valued at about $2.8 billion when Silver Lake invested in 2018, then went public in 2020 at a valuation near $12.7 billion. Slowing prescription volumes, a major pharmacy dispute, and broader pressure on unprofitable growth stocks cut its market capitalization to roughly $1.0 to $1.3 billion by mid-2026. The healthcare sector's marketing and consumer dynamics continue to shape demand for its price-comparison service.